# Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF

> **NCT04554056** · PHASE2,PHASE3 · COMPLETED · sponsor: **Mabwell (Shanghai) Bioscience Co., Ltd.** · enrollment: 586 (actual)

## Conditions studied

- Breast Cancer Female

## Interventions

- **DRUG:** MW05
- **DRUG:** PEG-rhG-CSF

## Key facts

- **NCT ID:** NCT04554056
- **Lead sponsor:** Mabwell (Shanghai) Bioscience Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-21
- **Primary completion:** 2022-08-20
- **Final completion:** 2022-11-05
- **Target enrollment:** 586 (ACTUAL)
- **Last updated:** 2022-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04554056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04554056, "Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04554056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*